Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/45685 |
Resumo: | © 2020 Eurasian Journal of Pulmonology Published by Wolters Kluwer - Medknow. |
id |
RCAP_5f56c6065f52b6533e4a24a1b3ad23dd |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/45685 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease?AsthmaBronchodilation criteriaBronchodilator responseChronic obstructive pulmonary disease© 2020 Eurasian Journal of Pulmonology Published by Wolters Kluwer - Medknow.Introduction: Currently, the bronchodilator reversibility is not recommended to differentiate asthma from chronic obstructive pulmonary disease (COPD); however, physiopathological specificities of each disease contribute to the differences in response to the drug. Objectives: The objective of this study is to evaluate the differences in bronchodilator response between asthmatic and COPD patients and to determine which of the bronchodilation criteria have the best ability to detect the positive response in these patients. Materials and methods: This was a cross-sectional study. The sample included 104 patients with asthma or COPD who performed lung function tests between January and March 2018. The whole sample was analyzed according to postbronchodilator variation (Δ) of lung function parameters, and the postbronchodilator reversibility was characterized using a multiple bronchodilation criteria. The drug used in reversibility test was salbutamol. Results: In this study, Δ forced-expiratory volume in the 1st s (ΔFEV1) and a Δ Raw was statistically higher in the group with asthma compared with the group with COPD. In the asthma group, the criteria ↓ functional residual capacity (FRC) ≥10%, ↓Raw ≥ 35%, ↑ forced expiratory flow between 25% and 75% of vital capacity (FEF25%–75%) ≥20% and ↑ FEV1 and / or ↑ forced vital capacity ≥12% and 200 mL were those that presented a greater capacity of detecting a positive response to bronchodilator. The criteria ↑ FEF25%–75%≥20% and ↓ FRC ≥ 10% were those that had the greater ability of detecting airway reversibility in COPD group. Conclusion: The analysis of postbronchodilator FEV1 and raw modifications as well as the using of a combination of multiple bronchodilation criteria contribute to a deeper characterization of bronchodilator reversibility in asthma and COPD.Wolters KluwerRepositório da Universidade de LisboaBarros, RaquelCamões De Araújo, PatríciaMourato, CláudiaBudzak, KhrystynaOliveira, AnaBárbara, Cristina2021-01-06T14:23:24Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/45685engEurasian J Pulmonol 2020;22:169-742148-362010.4103/ejop.ejop_16_202148-5402info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:47:38Zoai:repositorio.ul.pt:10451/45685Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:58:02.757086Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease? |
title |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease? |
spellingShingle |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease? Barros, Raquel Asthma Bronchodilation criteria Bronchodilator response Chronic obstructive pulmonary disease |
title_short |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease? |
title_full |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease? |
title_fullStr |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease? |
title_full_unstemmed |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease? |
title_sort |
Bronchodilator reversibility : what are the differences between asthma and chronic obstructive pulmonary disease? |
author |
Barros, Raquel |
author_facet |
Barros, Raquel Camões De Araújo, Patrícia Mourato, Cláudia Budzak, Khrystyna Oliveira, Ana Bárbara, Cristina |
author_role |
author |
author2 |
Camões De Araújo, Patrícia Mourato, Cláudia Budzak, Khrystyna Oliveira, Ana Bárbara, Cristina |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Barros, Raquel Camões De Araújo, Patrícia Mourato, Cláudia Budzak, Khrystyna Oliveira, Ana Bárbara, Cristina |
dc.subject.por.fl_str_mv |
Asthma Bronchodilation criteria Bronchodilator response Chronic obstructive pulmonary disease |
topic |
Asthma Bronchodilation criteria Bronchodilator response Chronic obstructive pulmonary disease |
description |
© 2020 Eurasian Journal of Pulmonology Published by Wolters Kluwer - Medknow. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020 2020-01-01T00:00:00Z 2021-01-06T14:23:24Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/45685 |
url |
http://hdl.handle.net/10451/45685 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Eurasian J Pulmonol 2020;22:169-74 2148-3620 10.4103/ejop.ejop_16_20 2148-5402 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Wolters Kluwer |
publisher.none.fl_str_mv |
Wolters Kluwer |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134525776723968 |